The aim of the present study was to determine the relative intratumoral activity of two pyrimidine biosynthetic enzymes, i.e. thymidylate synthase (TS) and thymidine kinase (TK), in human colorectal cancers to compare their possible relationship with demographic and pathologic characteristics of the patients and their tumors, and moreover to evaluate their predictive significance regarding 5-fluorouracil (5-FU) sensitivity and the overall survival of patients, respectively. TS and TK levels were significantly increased in the tumor compared to peritumoral tissue. However, no significant relationship between TS/TK activity and demographic features of the patients or pathologic characteristics of their tumors could be demonstrated. Kaplan-Meier analysis showed that the overall survival of patients with low TS activity was significantly longer (p < 0.012) compared to those with high TS activity. Such a difference could not be demonstrated between patients with high or low TK activity; however, combined evaluation of the two parameters proved that TK may contribute to the more precise assessment of disease prognosis, and it may further influence treatment decisions, i.e. the selection of patients for adjuvant therapy with 5-FU and folinic acid. Multivariate analysis showed that among the variables tested, beside Dukes’ stage, TS and TK activities were significant prognostic factors for the overall survival of colorectal cancer patients.

Keywords:
Thymidylate synthase, Thymidine kinase, Colorectal cancer, Prognosis
1.
Köves I: Treatment of colorectal cancers and premalignant lesions (in Hungarian). Lege Artis Med 1996;6:180–188.
2.
Astler VB, Coller FA: The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954;192:846–850.
3.
Cohen AM, Tremiterra S, Candela F, Thaler HT, Sigurdson ER: Prognosis of node-positive colon cancer. Cancer 1991;67:1859–1861.
4.
McLeod HL, Murray GI: Tumour markers of prognosis in colorectal cancer. Br J Cancer 1999;79:191–203.
5.
Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640–2647.
6.
Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP, Leichman CG: p53 point mutation and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival. Clin Cancer Res 1998;4:1243–1250.
7.
Lenz HJ, Danenberg KD, Leichman CG, Florentine B, Johnston PG, Groshen S, Zhou L, Xiong YP, Danenberg PV, Leichman LP: p53 and thymidylate synthase expression in un-treated stage II colon cancer: Association with recurrence, survival, and site. Clin Cancer Res 1998;4:1227–1234.
8.
Edler LD, Kressner U, Ragnhammar P, Johnston PG, Magnusson I, Glimelius B, Påhlman L, Lindmark G, Blomgren H: Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival. Clin Cancer Res 2000;6:488–492.
9.
Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumours. Cancer Res 1995;55:1407–1412.
10.
Leichman L, Lenz HJ, Leichman CG, Groshen S, Danenberg KD, Baranda J, Spears CP, Boswell W, Silberman H, Ortega A, Stain S, Beart R, Danenberg P: Quantitation of intratumoural thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial. Eur J Cancer 1995;7/8:1306–1310.
11.
Peters GJ, van der Wilt CL, van Triest B, Codacci-Pisanelli G, Johnston PG, van Groeningen CJ, Pinedo HM: Thymidylate synthase and drug resistance. Eur J Cancer 1995;31A:1299–1305.
12.
Romain S, Christensen IJ, Chinot O, Balslev I, Rose C, Martin PM, Thorpe SM: Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer. Int J Cancer 1995;61:7–12.
13.
Lewenhaupt A, Ekman P, Eneroth P, Nilsson B: Tumour markers as prognostic aids in prostatic carcinoma. Br J Urol 1990;66:182–187.
14.
Yusa T, Tamiya N, Yamaguchi Y, Takeda T, Ogawa T, Kimura H, Fujimura S: A study of thymidine kinase activity in lung cancer tissue. Jpn J Thorac Dis 1994;32:211–215.
15.
Denton JE, Lui MS, Aoki T, Sebolt J, Takeda E, Eble JN, Glover JL, Weber G: Enzymology of pyrimidine and carbohydrate metabolism in human colon carcinomas. Cancer Res 1982;42:1176–1183.
16.
Luccioni C, Beumatin J, Bardot V, Lefrancois D: Pyrimidine nucleotide metabolism in human colon carcinomas: Comparison of normal tissues, primary tumours and xenografts. Int J Cancer 1994;58:517–522.
17.
Roberts DW: An isotopic assay for thymidylate synthetase. Biochemistry 1966;5:3546–3548.
18.
Klemperer G, Haynes GR: Thymidine kinase in rat liver during development. Biochem J 1968;108:541–545.
19.
Hartree EF: Determination of protein A modification of the Lowry method which gives a linear photometric response. Anal Biochem 1970;48:422.
20.
Ahmed NK, Haggitt RC, Welch AD: Enzymes of salvage and de novo pathways of synthesis of pyrimidine nucleotides in human colorectal adeno-carcinomas. Biochem Pharmacol 1982;31:2485–2488.
21.
Peters GJ, van Groeningen CJ, Laurensee EI, Pinedo HM: A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 1991;68:1903–1909.
22.
Herzfeld A, Raper SM: Relative activities of thymidylate synthetase and thymidine kinase in rat tissues. Cancer Res 1980;40:744–750.
23.
Lasserre C, Sabatier L, Beaumatin J, Luccioni C, Lefrancois D, Muleris M, Dutrillaux B: Gene dosage and expression, and enzyme activity of thymidine kinase and thymidylate synthase in xenografted colorectal adenocarcinomas. Int J Cancer 1994;56:506–511.
24.
Van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, van der Wilt CL, van Laar JAM, Noordhuis P, Jansen G, Peters GJ: Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate based thymidylate synthase inhibitors in 13 nonselected colon cancer cell lines. Clin Cancer Res 1999;5:643–645.
25.
Van Triest B, Pinedo HM, Blaauwgeers JLG, van Diest PJ, Schoenmakers PS, Voorn DA, Smid K, Hoekman K, Hoitsma HFW, Peters GJ: Prognostic role of thymidylate synthase and thymidine phosphorylase/platelet derived endothelial growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000;6:1063–1072.
26.
Etienne MC, Chéradame S, Fischel JL, Formento P, Dassonville O, Renée N, Schneider A, Thyss A, Demard F, Milano G: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995;13:1663–1670.
27.
Findlay MPN, Cunnigham D, Morgan G, Clinton S, Hardcastle A, Aherne GW: Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 1997;75:903–909.
28.
Chu E, Allegra CJ: The role of thymidylate synthase as an RNA binding protein. Bioessays 1996;18:191–198.
29.
Chu E, Copur SM, Ju J, Chen TM, Khleif S, Voeller DM, Mizunuma N, Patel M, Maley GF, Maley F, Allegra CJ: Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol 1999;19:1582–1594.
30.
Cascinu S, Aschele C, Barni S, Debernardis D, Baldo Ch, Tunesi G, Catalano V, Staccioli MP, Brenna A, Muretto P, Catalano G: Thymidylate synthase protein expression in advanced colon cancer: Correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 1999;5:1996–1999.
31.
Ardalan B, Que BG: Enhanced gene expression of thymidylate synthase and thymidine kinase in fluoropyrimidine resistant human colon cancer cell line. Proc Am Assoc Cancer Res 2000;41:749.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.